Merck & Co., Inc. Lagevrio revenue
Lagevrio revenue at Merck & Co., Inc. came to $17.0M for the quarter to 30 Sep 2026, down 87.7% from a year earlier.
As Merck & Co., Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.
By quarter
| Period ending | Lagevrio revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $17.0M | down 87.7% | 4 Nov 2026 |
| 30 Jun 2026 | $5.0M | down 94.0% | 7 Aug 2026 |
| 31 Mar 2026 | $28.0M | down 72.5% | 4 May 2026 |
| 31 Dec 2025 | $57.0M | down 52.9% | 24 Feb 2026 |
| 30 Sep 2025 | $138.0M | down 64.0% | 5 Nov 2025 |
| 30 Jun 2025 | $83.0M | down 24.5% | 5 Aug 2025 |
| 31 Mar 2025 | $102.0M | down 70.9% | 2 May 2025 |
| 31 Dec 2024 | $121.0M | down 37.0% | 25 Feb 2025 |
| 30 Sep 2024 | $383.0M | down 40.2% | 6 Nov 2024 |
| 30 Jun 2024 | $110.0M | down 45.8% | 5 Aug 2024 |
| 31 Mar 2024 | $350.0M | down 10.7% | 3 May 2024 |
| 31 Dec 2023 | $192.0M | down 76.7% | 26 Feb 2024 |
| 30 Sep 2023 | $640.0M | up 46.8% | 3 Nov 2023 |
| 30 Jun 2023 | $203.0M | down 82.8% | 7 Aug 2023 |
| 31 Mar 2023 | $392.0M | down 87.9% | 5 May 2023 |
| 31 Dec 2022 | $825.0M | down 13.3% | 24 Feb 2023 |
| 30 Sep 2022 | $436.0M | — | 3 Nov 2022 |
| 30 Jun 2022 | $1.2B | — | 5 Aug 2022 |
| 31 Mar 2022 | $3.2B | — | 5 May 2022 |
| 31 Dec 2021 | $952.0M | — | 25 Feb 2022 |
| 30 Sep 2021 | $0 | — | 5 Nov 2021 |
| 30 Jun 2021 | $0 | — | 9 Aug 2021 |
| 31 Mar 2021 | $0 | — | 5 May 2021 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Merck & Co., Inc.: Keytruda revenue · Gardasil/Gardasil 9 revenue · Livestock revenue · Keytruda Qlex revenue · ProQuad/M-M-R II/Varivax revenue · Winrevair revenue · Companion Animal revenue · Lynparza alliance revenue · Prevymis revenue · Welireg revenue · Lenvima alliance revenue · Capvaxive revenue · RotaTeq revenue · Vaxneuvance revenue · Janumet revenue · Januvia revenue · Ohtuvayre revenue · Reblozyl alliance revenue · Bridion revenue · Adempas/Verquvo alliance revenue · Zerbaxa revenue · Adempas revenue · Delstrigo revenue · Isentress/Isentress HD revenue · financial statements
Every KPI and segment of MRK, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
